ArticleFrontiers in nutrition2025
Global, regional, and national burden of high body-mass index-related cancers and associated preventable life expectancy loss from 1990 to 2021.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A high Body Mass Index (BMI) is a key modifiable risk factor for cancer incidence. Therefore, it is essential to monitor the evolving trends and impact of cancer linked to high BMI and to formulate suitable strategies to address this issue. This study aims to analyze, from 1990 to 2021, the burden and temporal trends of cancer attributable to BMI as well as their impact on life expectancy, with major patterns highlighted by sex, socio-demographic index (SDI), and geographical region. Methods: Utilizing data from the Global Burden of Disease Study 2021, which incorporates 328,938 data sources, we conducted a comprehensive analysis of cancer attributable to high BMI, specifically investigating mortality rates and disability-adjusted life years (DALYs) from 1990 to 2021. Age-standardized rates were used to facilitate cross-regional comparisons, accounting for differences in population size and demographics. The Socio-demographic Index (SDI) was employed to categorize regions and evaluate correlations between cancer burden and economic development. In addition, we used the abridged period life table to estimate the impact of high BMI-related cancer on life expectancy. Results: The age-standardized death and DALY rates of cancer linked to high BMI increased (average annual percent change, 0.4 (95% UI: 0.4-0.5) for mortality and 0.5 (95% UI: 0.4-0.6) for DALY) from 1990 to 2021. The age-standardized death and DALY rates of cancer associated with high BMI were higher in females than in males globally. The alarming proportional increase in deaths from the main cancer associated with high BMI was observed among younger age groups (<45 years) from 1990 to 2021. In 2021, the most significant increases in life expectancy at birth were observed in regions with a high socio-demographic index, with gains of 0.12 (95% CI: -0.45-0.69) years for males and 0.19 (95% CI: -0.35-0.73) years for females, respectively. It is predicted that the age-standardized death rate of cancer attributable to high BMI will increase from 3.31 (3.29-3.33) in 2021 to 3.32 (1.27-5.37) by 2046 in males, and from 4.36 (4.38-4.39) to 4.90 (1.96-7.86) in females. Conclusion: The age-standardized mortality and DALY rates of cancer linked to high BMI have increased substantially, with significant differences across sex, geographic region, and SDI. Interventions aimed at reducing exposure are crucial not only to mitigate the cancer burden attributable to high BMI effectively, but also to yield modest gains in life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.